Article record

欧洲和北美儿童及青少年中EBV归因性癌症：一项荟萃分析

Epstein-Barr virus-attributable cancers among children and adolescents in Europe and North America: a meta-analysis.

综述 Meta鼻咽癌IF 9.3Q1

文献信息

PMID	42820761
原文	在 PubMed 查看原文 ↗
发表日期	2026
作者	Karena D Volesky-Avellaneda 查看其他 7 位作者 Olga Tsyruk-Romano；Allan Hildesheim；Stephen D Walter；Mariam El-Zein；Christine M Friedenreich；Darren R Brenner；Eduardo L Franco
作者单位	Division of Cancer Epidemiology, McGill University, Montreal, Quebec, Canada. 查看其他 6 条单位信息 Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.；Department of Medicine, Western University, London, Ontario, Canada.；Agencia Costarricense de Investigaciones Biomedicas, San Jose, Costa Rica.；Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.；Department of Cancer Epidemiology and Prevention Research, Cancer Care Alberta, Calgary, Alberta, Canada.；Departments of Oncology and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
期刊	Journal of the National Cancer Institute
SCI 分区	Q1
IF	9.3
研究类型	综述 Meta · 临床
所属专科	鼻咽癌

中文摘要

背景： EBV是一种常见的儿童期感染，与伯基特淋巴瘤、霍奇金淋巴瘤和鼻咽癌相关。我们估计了2022年欧洲和北美年龄≤19岁人群中归因于EBV的癌症比例和数量。
方法： 检索了Embase和MEDLINE，从建库至2025年8月25日。癌症发病率来自GLOBOCAN。我们纳入了对居住在欧洲或北美的≥8名年龄≤19岁个体的癌症组织进行EBV检测的研究。使用随机效应模型估计合并EBV患病率和95%置信区间（CI）。为了获得EBV归因病例，将合并患病率乘以癌症发病率。
结果： 在筛选了17,388篇标题/摘要和1,084篇全文后，53项研究符合伯基特淋巴瘤（9项研究，433例）、霍奇金淋巴瘤（40项研究，3197例）和鼻咽癌（4项研究，62例）的纳入标准。EBV的合并患病率在伯基特淋巴瘤中为19.7%（CI：10.2-34.7%，I2=69.5%），在霍奇金淋巴瘤中为33.4%（CI：27.4-40.0%，I2=75.6%），在鼻咽癌中为96.8%（CI：88.0-99.2%，I2=0.0）。估计2022年诊断的41,366例癌症中有1,166例（2.8%）归因于EBV。这些病例包括899例霍奇金淋巴瘤、140例伯基特淋巴瘤和127例鼻咽癌。男性（3.2% vs 女性2.3%）和10-14岁年龄组（5.0% vs 0-9岁1.7%和15-19岁3.1%）的负担更高。
结论： 2022年，欧洲和北美诊断的儿童癌症中有2.8%归因于EBV。

英文摘要

BACKGROUND: Epstein-Barr virus (EBV), a common childhood infection, is associated with Burkitt lymphoma, Hodgkin lymphoma, and nasopharyngeal cancer. We estimated the proportion and number of cancers attributable to EBV among individuals aged ≤19 years in Europe and North America in 2022.
METHODS: Embase and MEDLINE were searched from inception to August 25th, 2025. Cancer incidence was derived from GLOBOCAN. We included studies where cancer tissue from ≥8 individuals aged ≤19 years residing in Europe or North America were tested for EBV. Pooled EBV prevalence and 95% confidence intervals (CIs) were estimated using random-effects models. To obtain EBV-attributable cases, pooled prevalence was multiplied by cancer incidence.
RESULTS: After screening 17,388 titles/abstracts and 1,084 full-texts, 53 studies met the inclusion criteria for Burkitt lymphoma (9 studies, 433 cases), Hodgkin lymphoma (40 studies, 3197 cases), and nasopharyngeal cancer (4 studies, 62 cases). The pooled prevalence of EBV was 19.7% (CI: 10.2-34.7%, I2=69.5%) in Burkitt lymphoma, 33.4% (CI: 27.4-40.0%, I2=75.6%) in Hodgkin lymphoma, and 96.8% (CI: 88.0-99.2%, I2=0.0) in nasopharyngeal cancer. An estimated 1,166 (2.8%) of 41,366 cancers diagnosed in 2022, were attributable to EBV. These cases comprised 899 Hodgkin lymphomas, 140 Burkitt lymphomas, and 127 nasopharyngeal cancers. The burden was higher among males (3.2% vs 2.3% for females) and those aged 10-14 years (5.0% vs 1.7% for 0-9-year-olds and 3.1% for 15-19-year-olds).
CONCLUSION: In 2022, 2.8% of childhood cancers diagnosed in Europe and North America were attributable to EBV.